cyproterone has been researched along with Inflammation* in 2 studies
1 trial(s) available for cyproterone and Inflammation
| Article | Year |
|---|---|
A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa.
In order to examine whether anti-androgen therapy was effective in hidradenitis suppurativa (HS), ethinyloestradiol 50 micrograms/cyproterone acetate 50 mg in a reverse sequential regimen was compared with ethinyloestradiol 50 micrograms/norgestrel 500 micrograms (Eugynon 50) in 24 female patients. Both treatments produced substantial improvement in disease activity. Seven patients cleared and have remained free of disease for 18 months, five patients improved, four remained unchanged, while two deteriorated. Cyproterone acetate was not clinically significantly more effective than E50, and both gave a similar reduction in free androgen index. Anti-androgen therapy appears to be beneficial in the treatment of hidradenitis suppurativa. Topics: Adult; Androgens; Apocrine Glands; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ethinyl Estradiol; Female; Humans; Inflammation; Norgestrel; Sweat Gland Diseases; Sweat Glands | 1986 |
1 other study(ies) available for cyproterone and Inflammation
| Article | Year |
|---|---|
Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy.
The effects of combined treatment with the antiandrogen, cyproterone acetate, and ethinyl oestradiol on four women with long-standing hidradenitis suppurativa have been investigated. The condition was controlled successfully in all patients with 100 mg/day cyproterone acetate using the reversed sequential regimen; lowering the antiandrogen to 50 mg/day caused deterioration. Before treatment, plasma testosterone levels were within the normal range, but plasma androstenedione values were raised and sex hormone binding globulin levels were low. On treatment, the androstenedione concentration fell and sex hormone-binding globulin values were raised. However, since these levels were unaltered by reducing the antiandrogen dosage, the main action of the therapy is probably that of the antiandrogen within the target cells. Topics: Adult; Androgens; Apocrine Glands; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Humans; Inflammation; Sebum; Sex Hormone-Binding Globulin; Sweat Gland Diseases; Sweat Glands | 1986 |